target price: $2.03 gxy report, page-5

At this stage its not a matter of price; its a matter of risk.

I'd need to see the result of the test run from the carbonate plant &
and the real costs of spodumene from Mt Catlin announced.

This would give an indication of potential profitability and if favourable
would reduce the risk of further cap raises and make GXY a reasonable
investment.

Once this info is known one can have a reasonable shot at estimating
sp based on forecast eps.

Hope that helps

Cheers
Moorookamick
Dublin